Similar Effectiveness of Both Formulations of Tocilizumab (TCZ) in Patients with Rheumatoid Arthritis (RA) Switching from Intravenous (IV) to Subcutaneous (SC) at 6 Months in Real Life

Jean Darloy , Rene-Marc Flipo (1, 2) , Nicolas Segaud , Jean-Paul Eschard (3) , Vincent Goeb (4) , Jean-Hugues Salmon (5) , Eric Houvenagel (6) , Clement Chopin (7) , Samuel Gally , David Pau (8) , Isabelle Idier (9) , Guy Baudens (10)

1 Hôpital Roger Salengro [Lille]
2 CHU Lille
3 CHU Reims - Centre Hospitalier Universitaire de Reims
4 AMIENS - Rhumato - Service de Rhumatologie - AMIENS
5 Hôpital Maison Blanche
6 UCL - Université catholique de Lille
7 ASTRO - Agrosystèmes tropicaux
8 Roche France
9 Chugai Pharma France, Paris La Défense
10 Cabinet de Rhumatologie, Valenciennes

Domaines: Sciences du Vivant [q-bio]

Jean Darloy, Rene-Marc Flipo, Nicolas Segaud, Jean-Paul Eschard, Vincent Goeb, et al.. Similar Effectiveness of Both Formulations of Tocilizumab (TCZ) in Patients with Rheumatoid Arthritis (RA) Switching from Intravenous (IV) to Subcutaneous (SC) at 6 Months in Real Life. Arthritis & rheumatology, 2017, 69 (10). ⟨hal-03606091⟩